Overview

A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This is a study of the safety and efficacy of ustekinumab (CNTO 1275) in adolescent patients with moderate to severe psoriasis.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Ustekinumab